CNAT News Alert Conatus Pharmaceuticals Inc (CNAT) 10.63 01/06/2015

New Post Public Reply Private Reply Replies (0) Message Board

Jan 6, 2015 at 6:28 PM

Conatus Pharmaceuticals Inc (CNAT) 10.63 $CNAT

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - 53 mins ago

NGL: 26.51 (+0.19), BXS: 20.85 (-0.60), CFR: 65.85 (-1.65), AEM: 29.03 (+1.58), CNAT: 10.63 (+0.57), JCP: 6.56 (+0.12), AXTA: 27.71 (+1.03), SN: 8.39 (+0.05), WIFI: 7.48 (-0.17), OZRK: 34.67 (-1.08)

Is Conatus Poised For A Breakout?
Left Banker - at Seeking Alpha - Tue Jan 06, 1:42PM CST

CNAT: 10.63 (+0.57), PFE: 31.42 (+0.26)

Medtronic's (MDT) IN.PACT Admiral DCB Wins FDA Go-Ahead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 1:40PM CST
Medtronic's (MDT) IN.PACT Admiral DCB helps in reopening narrowed or blocked arteries located in the upper leg of a peripheral artery disease (PAD) patient.
ICUI: 80.48 (-0.09), BCR: 165.56 (+0.57), MDT: 71.22 (-0.36), CNAT: 10.63 (+0.57)

Zimmer Holdings Scales 52-Week High on Portfolio Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 12:55PM CST
With the grand $13.35 billion acquisition of Biomet, Zimmer (ZMH) expects to create a market leader in the $45 billion musculoskeletal industry
ZMH: 115.80 (-0.99), ICUI: 80.48 (-0.09), INSY: 43.04 (+0.32), CNAT: 10.63 (+0.57)

Stryker Acquires Assets of Canada-based CHG Hospital Beds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 12:30PM CST
The all-cash deal is expected to be neutral to Stryker Corporation's (SYK) 2015 earnings per share, barring acquisition, integration-related and intangible amortization charges and accretive thereafter.
ICUI: 80.48 (-0.09), SNN: 35.90 (+0.02), CNAT: 10.63 (+0.57), SYK: 92.41 (-0.13)

Gilead Acquires Drug Program For Fatty Liver Disease
at Investor's Business Daily - Tue Jan 06, 10:20AM CST
Big-cap biotech Gilead Sciences (GILD) agreed Tuesday to acquire a program from small German biotech Phenex Pharmaceuticals aimed at treating liver disease. Gilead agreed to an unspecified upfront payment and milestone payments totaling up to $470...
RPTP: 10.28 (-0.33), GILD: 97.65 (+0.86), CNAT: 10.63 (+0.57), ICPT: 160.01 (-16.99), FGEN: 35.06 (+1.27)

IPO Stock Watch: FibroGen Up With Liver-Disease Field
at Investor's Business Daily - Mon Jan 05, 3:40PM CST
Biotech FibroGen (FGEN) jumped 23% Monday to 33.83, a new high for a stock that went public at 18 on Nov. 13. FibroGen stock rose along with several other players in the liver-disease field, including Intercept Pharmaceuticals (ICPT), Conatus (CNAT)...
RPTP: 10.28 (-0.33), CNAT: 10.63 (+0.57), ICPT: 160.01 (-16.99), FGEN: 35.06 (+1.27)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 11:48AM CST

SD: 1.41 (-0.12), XENT: 20.23 (-0.50), WLL: 29.40 (-0.34), BTE: 14.21 (-0.50), BOTA: 2.65 (-0.20), CNAT: 10.63 (+0.57), WG: 5.40 (+0.01), SN: 8.39 (+0.05), LPI: 8.42 (-0.95), EROC: 2.16 (-0.04), BCLI: 5.00 (-0.75), NDRM: 15.45 (+1.80), SMLR: 2.69 (+0.34), QURE: 17.23 (+0.07), SFY: 3.23 (+0.07), ANTH: 2.20 (-0.07), PLX: 2.02 (-0.15), APRI: 1.31 (-0.03), STXS: 1.70 (-0.18), GST: 2.14 (-0.14)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 8:10AM CST

CERS: 5.78 (-0.79), E: 32.08 (+0.12), SSL: 34.64 (-0.36), CNAT: 10.63 (+0.57), SDRL: 10.48 (-0.33), NBG: 1.58 (-0.08), BCLI: 5.00 (-0.75), URZ: 1.20 (+0.02), PBR: 6.02 (-0.05), ISIS: 65.44 (-2.73), KITE: 71.45 (+1.70), PLX: 2.02 (-0.15), CEMP: 23.15 (-1.40), STXS: 1.70 (-0.18)

Conatus up big premarket
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 7:31AM CST

CNAT: 10.63 (+0.57)

Conatus to report results from three clinical trials on Thursday
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 6:27AM CST

CNAT: 10.63 (+0.57)

Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan
GlobeNewswire - Mon Jan 05, 6:23AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report top-line results from three clinical trials in subjects with varying degrees of organ impairment - the company's Phase 2 trial in patients with acute-on-chronic liver failure (ACLF), Phase 1 trial in patients with mild, moderate and severe hepatic impairment, and Phase 1 trial in patients with severe renal impairment - after the market close on Thursday, January 8, 2015. Conatus will host a conference call and webcast with an associated presentation at 4:30 p.m. Eastern Time on Thursday, January 8, 2015, to discuss the trial results.
CNAT: 10.63 (+0.57)

The 2015 Calendar Of NASH Trial Catalysts Series Brings Huge Opportunities For Investors
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 2:29AM CST

RPTP: 10.28 (-0.33), CNAT: 10.63 (+0.57)

Conatus Pharmaceuticals: A Potential Double Worth Consideration
Bret Jensen - at Seeking Alpha - Sat Dec 13, 1:23PM CST

CNAT: 10.63 (+0.57)

Conatus Pharmaceuticals to Present at Two December Investor Conferences
GlobeNewswire - Mon Nov 24, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled participation in two upcoming investor conferences. The company is scheduled to participate in a "fireside chat" discussion with the covering research analyst at the 26th Annual Piper Jaffray Health Care Conference at 3:30 p.m. ET on Tuesday, December 2, 2014, in New York. The company is scheduled to deliver a formal presentation at the Oppenheimer 25th Annual Healthcare Conference at 11:30 a.m. ET on Wednesday, December 10, 2014, in New York.
CNAT: 10.63 (+0.57)

European Ad Comm gives thumbs up to AbbVie's HCV combo
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:48AM CST

GILD: 97.65 (+0.86), ACHN: 12.81 (-0.51), CNAT: 10.63 (+0.57), MRK: 60.32 (+2.28), RGLS: 15.68 (-0.56), ABBV: 64.33 (-0.32), BMY: 58.48 (-0.10), ENTA: 48.88 (-1.04)

2 Attractive But Speculative Biotech Gems For Consideration
Bret Jensen - at Seeking Alpha - Fri Nov 14, 8:17AM CST

AGEN: 3.91 (-0.26), CNAT: 10.63 (+0.57)

Conatus Pharmaceuticals' (CNAT) CEO Steven Mento on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 7:05PM CST

CNAT: 10.63 (+0.57)

Conatus Pharmaceuticals beats by $0.02
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:04PM CST

CNAT: 10.63 (+0.57)

Conatus Pharmaceuticals Reports Third Quarter 2014 Financial Results and Program Updates
GlobeNewswire - Wed Nov 12, 3:02PM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and nine months ended September 30, 2014, and provided updates on its clinical development programs.
CNAT: 10.63 (+0.57)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Solstice Advances Foam Agent with Eco-Friendly Twist

A New Phase in Foam Blowing Agents You don’t come across a true leap in materials technology every day, and that’s exactly what's unfolding with Solstice Advanced Materials' latest venture. They’re not just talking the talk; they've hit a milestone in developing a next-gen foam blowing agent. This isn't just another tweak in a spreadsheet—it's a potential pivot in...

Formation Unveils First Solana Tokenized Securities Venue

Well, here we go. Formation Securities is setting sail on the high seas of blockchain, aiming to operate a tokenized securities venue (TSV) on Solana. This isn't your garden-variety launch—it's a bold leap into a newer, faster-paced world of trading. Sure, you’ve heard about blockchains before, but this operation marries the traditional rigmarole of the stock market...

Outpace SEO Claims Impressive 3.7x Client ROI Boost

Outpace SEO's Bold Promise: A Data-Driven Success The SEO game isn't for the faint-hearted. You either step up or get left behind. Outpace SEO, hailing from Oklahoma City, has decided to set their own rules with a boastful claim of a 3.7x return on investment (ROI) for their clients. That kind of promise sets the bar high, and it's tied to their data-driven approach to...

Texas Author's Memoir Journeys Through Trauma and Growth

Finding Clarity Amid Chaos When life throws the unexpected, some folks crumble, but others, like Joyce L. Skala, sift through the rubble for clarity. Her debut memoir, "There's No Such Thing as Bad," weaves through personal chaos—embracing trauma and loss like a late-night poker game where the house always wins. Born from the charred memories of her family's home...

Creality's Kid-Friendly AI 3D Printer Debuts at $329

Creality Unpacks mBox for Young Innovators You squint at the market to find the next big thing, and here comes Creality tossing a fancy innovation into the ring. Meet the mBox—a kid-operated, AI-driven 3D printer. This little contraption is set to spark youthful imagination, not just buzz amongst hobbyist circles. They're rolling this out on TikTok Shop from November 9...

Tech Vet's Career Shift: Seniors Helping Seniors Launches

From Silicon Valley Hustle to Heartfelt Care So, Lindsey Keefner, a seasoned pro from Pasadena's tech scene, is ditching the buzz of artificial intelligence to focus on something raw and real—human connection. After two decades of tech gigs, this ex-exec is launching a branch of Seniors Helping Seniors® in Pasadena-Glendale. And let me tell you, this isn't about profit...

ZEISS Expands in China: Tackling Myopia's Surge

ZEISS Sets Sights on China’s Myopia Epidemic They're calling myopia a public health crisis in China, and if you've seen the statistics, that's no exaggeration. Enter ZEISS Medical Technology, angling for a piece of the pie with their newly NMPA-approved PT LUNANA phakic intraocular lens. This is more than just another medical product, folks. It's a strategic entry into...

Telespazio & Rivada Forge Secure Satellite Network

Rivada's Outernet: A New Era of Connectivity Forget the terrestrial wires; we're talking about 600 satellites playing a space-age game of telephone. That's Rivada's Outernet for you, an orbital mesh network that's about to upend the very nature of global communications. Telespazio's new partnership with Rivada is like strapping a rocket onto secure connectivity in the...

OpenAssets Sets Up Shop in Abu Dhabi, Joins Hub71

OpenAssets Carves a Niche in Abu Dhabi OpenAssets has just staked a claim in the Middle East by setting up its headquarters in the Abu Dhabi Global Market (ADGM). Picture this: a digital asset infrastructure provider unfurling its wings in one of the most dynamic economic landscapes—it's like watching a rookie clinch the game at the stock pit. But there's more, folks....

Trimble's AI Tool Tackles Chronically Delayed Projects

Facing Down Delays with Trimble's New AI Tool In an industry where timelines are often more of a suggestion than a rule, Trimble's dropping a new hammer with its Connect Scheduling solution. This isn't your garden-variety update; it's a full-fledged assault on the inefficiencies plaguing construction scheduling today. With Trimble Connect Scheduling, folks on the ground...